Inclacumab fails, and osivelotor is on hold.
ApexOnco Front Page
Recent articles
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
Shortly after ponsegromab, visugromab is to start phase 2/3.
Meanwhile, ASK Pharm challenges Hutchmed in cMet.
Progress with three bispecific molecules is rewarded with a $120m equity raise.
Keynote-D18 might have failed on a technicality, but now cash is running out.
ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
